Viking therapeutics, inc.VKTX.US Overview
VKTX Overall Performance
VKTX AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
VKTX Current Performance
1.70%
Viking therapeutics, inc.
1.27%
Avg of Sector
-0.32%
S&P500
VKTX Key Information
VKTX Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
VKTX Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
VKTX Profile
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Price of VKTX
VKTX FAQ
When is VKTX's latest earnings report released?
The most recent financial report for Viking therapeutics, inc. (VKTX) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating VKTX's short-term business performance and financial health. For the latest updates on VKTX's earnings releases, visit this page regularly.
How much debt does VKTX have?
As of the end of the reporting period, Viking therapeutics, inc. (VKTX) had total debt of 878K, with a debt ratio of 0. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does VKTX have?
At the end of the period, Viking therapeutics, inc. (VKTX) held Total Cash and Cash Equivalents of 33.93M, accounting for 0.04 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is VKTX's EPS continuing to grow?
According to the past four quarterly reports, Viking therapeutics, inc. (VKTX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.58. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of VKTX?
Viking therapeutics, inc. (VKTX)'s Free Cash Flow (FCF) for the period is -47.06M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 65.05% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of VKTX?
The latest valuation data shows Viking therapeutics, inc. (VKTX) has a Price-To-Earnings (PE) ratio of -21.89 and a Price/Earnings-To-Growth (PEG) ratio of -0.27. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.